Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Dose-Escalation Study of CNF2024 Administered Orally to Patients With B Cell Chronic Lymphocytic Leukemia (CLL)

NCT00344786 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT00344786
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00344786 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Dose-Escalation Study of CNF2024 Administered Orally to Patients With B Cell Chronic Lymphocytic Leukemia (CLL)
Lead sponsor
Biogen
Phase
Phase 1
Overall status
Terminated
Start date
February 28, 2006
Completion date
September 30, 2008
Enrollment
15 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell chronic lymphocytic leukemia